What is the typical dose of Tesofensine?

Typical research doses are 0.25-1 mg, administered 1x daily. Commonly timed: Morning. These are research figures only — not clinical recommendations.

What are the known side effects of Tesofensine?

Side effects reported in research include: Nausea (common, mild); Insomnia or sleep disturbance (common, mild); Increased heart rate (tachycardia) (common, moderate); Elevated blood pressure (common, moderate); Headache (uncommon, mild); Dry mouth (uncommon, mild); Anxiety or nervousness (uncommon, mild); Tremor (uncommon, mild); Sweating (uncommon, mild); Constipation (uncommon, mild); Serotonin syndrome (rare, serious); Psychiatric symptoms (rare, serious); Arrhythmia (rare, serious). Always consult a qualified professional before use.

How is Tesofensine administered?

Tesofensine is typically administered via Oral.

What is the evidence quality for Tesofensine?

Tesofensine carries an evidence grade of B. Grade B — supported by human observational studies or smaller trials.

Metabolic & Weight Loss / Oral

Tesofensine

Q: What is Tesofensine used for in research?

Research on Tesofensine has focused on: Reduces appetite and food intake; Increases energy expenditure and metabolic rate; Promotes weight loss in obesity; Enhances alertness and wakefulness; Improves mood and motivation; Reduces food cravings.

Also known as NN7952

Triple monoamine reuptake inhibitor that significantly suppresses appetite and increases energy expenditure. Originally developed for neurological conditions, repurposed for obesity treatment.

What is Tesofensine used for? Research has focused on reduces appetite and food intake; increases energy expenditure and metabolic rate; promotes weight loss in obesity.

Compare with other peptides studied forfat loss,muscle growth,anxiety and mood

Evidence grade BResearch only

Beginner basics

Plain-English guide to Tesofensine

What it does: This compound works by increasing a brain chemical that reduces hunger and makes your body burn more calories throughout the day. Researchers study it for weight loss because it makes people feel less hungry and more energetic.
Typical dose: Researchers typically start with 0.25 mg by mouth once daily, then increase by 0.25 mg every 4 weeks up to a maximum of 1 mg daily, depending on how well someone tolerates it.
When to inject: Take it in the morning with or without food. Morning timing helps with the energy-boosting effects throughout the day.
Storage: Keep the dry powder in a freezer at -20°C (around -4°F). Once mixed with liquid, store it in a regular refrigerator at 2-8°C (35-46°F) and keep it away from direct light.
Beginner tip: Start at the lowest dose (0.25 mg) and give your body at least 4 weeks to adjust before increasing-this helps you see how you actually respond without jumping to higher amounts too quickly.

Research status

Evidence grade B: Smaller human trials, observational studies, or approved in 30 or more countries.
Research only: No regulatory approval in any major jurisdiction. Research use only.

Moderate Clinical Data

For research purposes only. Not approved for human use. Not medical advice.

Research areas

Reduces appetite and food intake
Increases energy expenditure and metabolic rate
Promotes weight loss in obesity
Enhances alertness and wakefulness
Improves mood and motivation
Reduces food cravings

Side effects

Effect	How often	Severity
NauseaOften transient and resolves within 1-2 weeks. Take with food if tolerated. Dose titration reduces incidence.	Common	Mild
Insomnia or sleep disturbanceDue to increased dopamine and norepinephrine. Take dose in early morning (6-8 AM). Avoid evening dosing. May improve with continued use.	Common	Mild
Increased heart rate (tachycardia)Dose-dependent effect. Monitor heart rate regularly. Baseline and periodic cardiovascular assessment recommended. Discontinue if sustained elevation or palpitations occur.	Common	Moderate
Elevated blood pressureNoradrenergic effect. Monitor blood pressure at baseline and regularly during treatment. Contraindicated in uncontrolled hypertension.	Common	Moderate
HeadacheUsually mild and transient. May respond to over-the-counter analgesics.	Uncommon	Mild
Dry mouthIncrease water intake. Use sugar-free lozenges if needed.	Uncommon	Mild
Anxiety or nervousnessDose-dependent. May occur during titration phase. Consider slower dose escalation.	Uncommon	Mild
TremorFine tremor may occur, particularly at higher doses. Usually resolves with dose reduction or continued use.	Uncommon	Mild
SweatingIncreased thermogenesis and sympathetic activation. Usually mild and transient.	Uncommon	Mild
ConstipationIncreased fiber intake and hydration recommended. Stool softeners may help if needed.	Uncommon	Mild
Serotonin syndromeRisk if combined with other serotonergic agents (SSRIs, SNRIs, MAOIs, tramadol). Symptoms include agitation, confusion, rapid heart rate, high blood pressure, dilated pupils, muscle rigidity. Requires immediate medical attention. Contraindicated with serotonergic medications.	Rare	Serious
Psychiatric symptomsMood changes, suicidal ideation, or behavioral changes reported in some users. Monitor mental health closely. Discontinue and seek medical evaluation if psychiatric symptoms emerge.	Rare	Serious
ArrhythmiaCardiac arrhythmias possible, particularly in susceptible individuals or at higher doses. Baseline ECG recommended. Discontinue immediately if arrhythmia suspected.	Rare	Serious

Dosing reference

Dose scale from the research

Starting: 0.25 mg
Typical: 0.5 mg
Upper end: 1 mg

Tesofensine dosing reference
Parameter	Value
Dose range	0.25-1 mg
Frequency, timing and route are for members Sign up free Log in

Checked October 2026

Research disclaimer. Figures are drawn from published research literature and community logs. They are not clinical recommendations. Consult a qualified professional. Research use only.

Reconstitution guide

Do not use saline or bacteriostatic saline, use only bacteriostatic water for reconstitution
Do not shake the vial vigorously; gentle swirling prevents peptide degradation
Discard immediately if the solution appears cloudy, discolored, or contains visible particles
Use within 30 days of reconstitution when stored at 2-8°C
Do not freeze the reconstituted solution; freezing may denature the peptide
Use the PeptideVolt reconstitution calculator for your exact concentration

Work out your exact dose in the free peptide calculator

Storage and stability

Store lyophilized peptide at -20°C. Refrigerate after reconstitution (2-8°C). Protect from light.

Molecular and pharmacological data

Half-life	Approximately 20-24 hours (oral)

Tesofensine is a triple monoamine reuptake inhibitor that blocks the reuptake of serotonin, norepinephrine, and dopamine in the central nervous system. By increasing synaptic concentrations of these neurotransmitters, it suppresses appetite through hypothalamic pathways and increases energy expenditure, promoting weight loss. It was originally developed for neurological conditions but has been repurposed for obesity treatment due to its potent metabolic effects.

Pathways and mechanism detail are for members

Keep a log of your Tesofensine research

Free account. No credit card required.

Start free Goal finder Interaction checker

Recent research

All results on PubMed

Source: PubMed / NCBI. Updated daily. Articles are listed for research reference only.

Research citations

4 sources

Astrup A, et al. (2021). Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, semaglutide. International Journal of Obesity. PMID: 33479548. Phase 2b trial demonstrating tesofensine's monoamine reuptake inhibition mechanism for weight loss.
Bloom SR, et al. (2012). The obesity drug pipeline: Targeting FTO, MC4R, POMC, and PPAR-gamma. Nature Reviews Drug Discovery. DOI: 10.1038/nrd3800. Reviews tesofensine as a triple monoamine reuptake inhibitor candidate for obesity.
Astrup A, et al. (2008). Tesofensine (NS2330), a novel triple monoamine reuptake inhibitor, for treatment of obesity. Obesity. PMID: 18535554. Early clinical trial showing appetite suppression and weight loss with tesofensine dosing.
Rasmussen MF, et al. (2007). Tesofensine, a novel triple monoamine reuptake inhibitor, in the treatment of obesity. Obesity. PMID: 17299084. Demonstrates dose-dependent weight loss and safety profile in obese subjects.

All Metabolic & Weight Loss peptides

Tesofensine in blends

Browse the research library

147 peptide profiles and 59 blend profiles with mechanism summaries, dosing data and reconstitution guides.

View all peptides

Stay updated on Tesofensine research

A weekly digest of new peptide research, stack guides and site updates.

Research use only. All content on this page is provided for informational and educational purposes related to scientific research. Tesofensine is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.